• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用合成E-钙黏蛋白肽调节小鼠血脑屏障通透性

Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.

作者信息

On Ngoc H, Kiptoo Paul, Siahaan Teruna J, Miller Donald W

机构信息

Department of Pharmacology and Therapeutics, University of Manitoba , Winnipeg, Manitoba, Canada.

出版信息

Mol Pharm. 2014 Mar 3;11(3):974-81. doi: 10.1021/mp400624v. Epub 2014 Feb 19.

DOI:10.1021/mp400624v
PMID:24495091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3993937/
Abstract

The present work characterizes the effects of synthetic E-cadherin peptide (HAV) on blood-brain barrier (BBB) integrity using various techniques including magnetic resonance imaging (MRI) and near-infrared fluorescent imaging (NIRF). The permeability of small molecular weight permeability marker gadolinium diethylenetriaminepentaacetate (Gd-DTPA) contrast agent, the large molecular weight permeability marker, IRDye 800CW PEG, and the P-glycoprotein (P-gp) efflux transporter contrast agent, rhodamine 800 (R800), were examined in the presence and absence of HAV peptide. The results consistently demonstrated that systemic iv administration of HAV peptide resulted in a reversible disruption of BBB integrity and enhanced the accumulation of all the dyes examined. The magnitude of increase ranged from 2-fold to 5-fold depending on the size and the properties of the permeability markers. The time frame for BBB disruption with HAV peptide was rapid, occurring within 3-6 min following injection of the peptide. Furthermore, modulation of BBB permeability was reversible with the barrier integrity being restored within 60 min of the injection. The increased BBB permeability observed following HAV peptide administration was not attributable to changes in cerebral blood flow. These studies support the potential use of cadherin peptides to rapidly and reversibly modulate BBB permeability of a variety of therapeutic agents.

摘要

本研究利用包括磁共振成像(MRI)和近红外荧光成像(NIRF)在内的多种技术,对合成的E-钙黏蛋白肽(HAV)对血脑屏障(BBB)完整性的影响进行了表征。在存在和不存在HAV肽的情况下,检测了小分子通透性标记物钆二乙烯三胺五乙酸(Gd-DTPA)造影剂、大分子通透性标记物IRDye 800CW PEG以及P-糖蛋白(P-gp)外排转运体造影剂罗丹明800(R800)的通透性。结果一致表明,全身静脉注射HAV肽会导致血脑屏障完整性的可逆性破坏,并增强所有检测染料的蓄积。根据通透性标记物的大小和性质,增加幅度在2倍至5倍之间。HAV肽破坏血脑屏障的时间框架很快,在注射肽后3-6分钟内发生。此外,血脑屏障通透性的调节是可逆的,屏障完整性在注射后60分钟内恢复。HAV肽给药后观察到的血脑屏障通透性增加并非归因于脑血流量的变化。这些研究支持了钙黏蛋白肽在快速、可逆地调节多种治疗药物血脑屏障通透性方面的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffed/3993937/58b2430efdba/mp-2013-00624v_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffed/3993937/58b2430efdba/mp-2013-00624v_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffed/3993937/58b2430efdba/mp-2013-00624v_0002.jpg

相似文献

1
Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.使用合成E-钙黏蛋白肽调节小鼠血脑屏障通透性
Mol Pharm. 2014 Mar 3;11(3):974-81. doi: 10.1021/mp400624v. Epub 2014 Feb 19.
2
Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.利用溶血磷脂酸快速可逆地增强血脑屏障通透性。
J Cereb Blood Flow Metab. 2013 Dec;33(12):1944-54. doi: 10.1038/jcbfm.2013.154. Epub 2013 Sep 18.
3
Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.利用近红外荧光(NIRF)成像技术评估血脑屏障(BBB)中的 P-糖蛋白活性。
Pharm Res. 2011 Oct;28(10):2505-15. doi: 10.1007/s11095-011-0478-6. Epub 2011 May 20.
4
Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LC-MS/MS and Gd-DTPA Using Magnetic Resonance Imaging.药物和磁共振成像造影剂的脑内递送:使用液相色谱-串联质谱法检测和定量测定CPT-Glu的脑内沉积以及使用磁共振成像测定钆喷酸葡胺的脑内沉积。
Mol Pharm. 2016 Feb 1;13(2):379-90. doi: 10.1021/acs.molpharmaceut.5b00607. Epub 2016 Jan 6.
5
Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.环化ADT肽对细胞间连接的调节作为一种可逆增加血脑屏障通透性的方法。
J Pharm Sci. 2015 Mar;104(3):1065-75. doi: 10.1002/jps.24309. Epub 2015 Jan 12.
6
Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.线性与环状组氨酸-丙氨酸-缬氨酸肽对血脑屏障通透性调节作用的比较:对分子向脑内递送的影响
J Pharm Sci. 2016 Feb;105(2):797-807. doi: 10.1016/S0022-3549(15)00188-4.
7
Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice.荧光标记白蛋白的近红外荧光成像:一种用于小鼠局灶性脑缺血后血脑屏障损伤无创光学成像的新方法。
J Neurosci Methods. 2009 May 30;180(1):126-32. doi: 10.1016/j.jneumeth.2009.03.002. Epub 2009 Mar 20.
8
Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.检测小鼠脑肿瘤模型中的血脑屏障(BBB)完整性。
J Neurooncol. 2013 Jan;111(2):133-43. doi: 10.1007/s11060-012-1006-1. Epub 2012 Nov 27.
9
The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound.超声聚焦诱导血脑屏障通透性变化及载药阿霉素向脑内的传递动力学
J Control Release. 2012 Aug 20;162(1):134-42. doi: 10.1016/j.jconrel.2012.06.012. Epub 2012 Jun 15.
10
A polymeric micelle magnetic resonance imaging (MRI) contrast agent reveals blood-brain barrier (BBB) permeability for macromolecules in cerebral ischemia-reperfusion injury.一种聚合物胶束磁共振成像(MRI)造影剂揭示了脑缺血再灌注损伤中大分子的血脑屏障(BBB)通透性。
J Control Release. 2017 May 10;253:165-171. doi: 10.1016/j.jconrel.2017.03.020. Epub 2017 Mar 18.

引用本文的文献

1
A combination of systemic mannitol and mannitol modified polyester nanoparticles for caveolae-mediated gene delivery to the brain.用于经小窝介导将基因递送至大脑的全身用甘露醇和甘露醇修饰的聚酯纳米颗粒组合。
Mol Ther Nucleic Acids. 2025 Feb 6;36(1):102480. doi: 10.1016/j.omtn.2025.102480. eCollection 2025 Mar 11.
2
Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery.增强中枢神经系统中的抗体暴露:摄取和清除机制以及改善脑内递送的策略
J Nanotheranostics. 2023 Dec;4(4):463-479. doi: 10.3390/jnt4040020. Epub 2023 Oct 2.
3
A Comprehensive Examination of the Role of Epigenetic Factors in Multiple Sclerosis.

本文引用的文献

1
Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.利用溶血磷脂酸快速可逆地增强血脑屏障通透性。
J Cereb Blood Flow Metab. 2013 Dec;33(12):1944-54. doi: 10.1038/jcbfm.2013.154. Epub 2013 Sep 18.
2
Transporter-based delivery of anticancer drugs to the brain: improving brain penetration by minimizing drug efflux at the blood-brain barrier.基于转运体的抗癌药物脑内递送:通过最小化血脑屏障处的药物外排来提高脑内渗透率
Curr Pharm Des. 2014;20(10):1499-509. doi: 10.2174/13816128113199990458.
3
Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.
对多发性硬化症中表观遗传因素作用的全面考察。
Int J Mol Sci. 2024 Aug 16;25(16):8921. doi: 10.3390/ijms25168921.
4
Mechanism of the blood-brain barrier modulation by cadherin peptides.钙黏蛋白肽调节血脑屏障的机制。
Explor Drug Sci. 2024;2(3):322-338. doi: 10.37349/eds.2024.00049. Epub 2024 Jun 26.
5
Selective Uptake of Macromolecules to the Brain in Microfluidics and Animal Models Using the HAVN1 Peptide as a Blood-Brain Barrier Modulator.利用 HAVN1 肽作为血脑屏障调节剂在微流控和动物模型中对脑的大分子的选择性摄取。
Mol Pharm. 2024 Apr 1;21(4):1639-1652. doi: 10.1021/acs.molpharmaceut.3c00775. Epub 2024 Feb 23.
6
Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery.突破壁垒:针对动态紧密连接的新型靶向方法以改善药物递送。
Adv Drug Deliv Rev. 2023 Aug;199:114905. doi: 10.1016/j.addr.2023.114905. Epub 2023 Jun 3.
7
Subcellular analysis of blood-brain barrier function by micro-impalement of vessels in acute brain slices.在急性脑切片中通过微刺穿血管对血脑屏障功能进行亚细胞分析。
Nat Commun. 2023 Jan 30;14(1):481. doi: 10.1038/s41467-023-36070-6.
8
Spermidine/Spermine N1-Acetyltransferase 1 ()-A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA.亚精胺/精胺N1-乙酰基转移酶1()——使用可电离脂质纳米颗粒递送小干扰RNA对胶质母细胞瘤细胞进行选择性致敏的潜在基因靶点。 (注:原文括号处内容缺失,翻译可能会稍显不完整)
Cancers (Basel). 2022 Oct 22;14(21):5179. doi: 10.3390/cancers14215179.
9
Peptide Shuttles for Blood-Brain Barrier Drug Delivery.用于血脑屏障药物递送的肽穿梭载体
Pharmaceutics. 2022 Sep 5;14(9):1874. doi: 10.3390/pharmaceutics14091874.
10
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration.衰老的大脑:神经退行性变的分子与细胞基础
Front Cell Dev Biol. 2021 Aug 13;9:683459. doi: 10.3389/fcell.2021.683459. eCollection 2021.
检测小鼠脑肿瘤模型中的血脑屏障(BBB)完整性。
J Neurooncol. 2013 Jan;111(2):133-43. doi: 10.1007/s11060-012-1006-1. Epub 2012 Nov 27.
4
Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.利用近红外荧光(NIRF)成像技术评估血脑屏障(BBB)中的 P-糖蛋白活性。
Pharm Res. 2011 Oct;28(10):2505-15. doi: 10.1007/s11095-011-0478-6. Epub 2011 May 20.
5
Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides.通过 E-钙黏蛋白肽增强血脑屏障的药物吸收和抑制细胞间紧密连接再封闭。
Mol Pharm. 2011 Feb 7;8(1):239-49. doi: 10.1021/mp100293m. Epub 2010 Dec 17.
6
P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.P-糖蛋白相关药物相互作用:临床重要性及疾病状态的考虑。
Expert Opin Drug Metab Toxicol. 2010 May;6(5):603-19. doi: 10.1517/17425251003610640.
7
Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.解决药物发现中的中枢神经系统(CNS)穿透问题:不断发展的新概念的基础和意义。
Chem Biodivers. 2009 Nov;6(11):2030-49. doi: 10.1002/cbdv.200900103.
8
Structure and function of the blood-brain barrier.血脑屏障的结构和功能。
Neurobiol Dis. 2010 Jan;37(1):13-25. doi: 10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5.
9
In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.体外P-糖蛋白测定法用于预测P-糖蛋白在中枢神经系统中与药物的体内相互作用。
Drug Metab Dispos. 2008 Feb;36(2):268-75. doi: 10.1124/dmd.107.017434. Epub 2007 Oct 25.
10
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.用于检测乳腺癌中人表皮生长因子受体2过表达的双标记曲妥珠单抗成像剂。
J Nucl Med. 2007 Sep;48(9):1501-10. doi: 10.2967/jnumed.107.042234.